On July 30, 2026, Health Canada authorized Moderna to move forward with a Phase I clinical trial for its candidate mRNA vaccine for Ebola disease caused by the Bundibugyo virus.
On July 30, 2026, Health Canada authorized Moderna to move forward with a Phase I clinical trial for its candidate mRNA vaccine for Ebola disease caused by the Bundibugyo virus.